Phase 3Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF)
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF)
- Sponsor
- Cytokinetics (Industry)
- Enrolment
- 1,800 planned
- Conditions
- Heart Failure; Heart Failure With Reduced Ejection Fraction
- Interventions
- Omecamtiv Mecarbil (OM); Placebo
- Ages
- adults, older adults
- Registry
- NCT06736574, CTIS2024-519219-32-00
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Primary outcomes
- Time to the first of event of CV death, HF event, LVAD implantation/cardiac transplantation, or stroke
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered